Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 15/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20165490 | 0.98 | SLC6A2 (0.96) | SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL3832571 | 0.85 | SLC6A2 (0.80) | SLC6A2SLC6A3SLC6A4HTR1A | |
| Hydrochloric Acid SCHEMBL14862180 | 0.83 | SLC6A2 (0.77) | SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL2300405 | 0.83 | SLC6A4 (0.71) | SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL24180233 | 0.82 | SLC6A2 (0.70) | SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL20615067 | 0.82 | SLC6A2 (0.70) | SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL14957434 | 0.80 | SLC6A2 (0.66) | SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL30945150 | 0.80 | SLC6A2 (0.66) | SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL20165474 | 0.79 | SLC6A2 (0.74) | SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL20256750 | 0.78 | SLC6A2 (0.64) | SLC6A2SLC6A3SLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541784-B1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2023-09-13 | — | — | EP | claimed |
| CN-109963834-B | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | 综合研究实验室瑞典股份公司 | 2023-04-14 | — | — | CN | claimed |
| US-10875829-B1 | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2020-12-29 | — | — | US | claimed |
| EP-3541784-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | Integrative Research Laboratories Sweden AB (SE) | 2019-09-25 | — | — | EP | claimed |
| WO-2018091687-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2018-05-24 | — | — | WO | claimed |
| EP-4739654-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3-(2,3-DIFLUOROPHENOXY)AZETIDINE AND USES THEREOF | Integrative Research Laboratories Sweden AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739308-A1 | 3-(2,3-DIFLUOROPHENOXY)AZETIDINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR USE IN THE TREATMENT AND/OR PREVENTION OF PATHOLOGICAL APATHY | Integrative Research Laboratories Sweden AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| CN-121548563-A | Pharmaceutically acceptable salts of 3- (2, 3-difluorophenoxy) azetidine and uses thereof | 综合研究实验室瑞典股份公司 | 2026-02-17 | — | — | CN | disclosed |
| CN-121511082-A | 3- (2, 3-Difluorophenoxy) azetidine or a pharmaceutically acceptable salt thereof for the treatment and/or prevention of pathological apathy | 综合研究实验室瑞典股份公司 | 2026-02-10 | — | — | CN | disclosed |
| WO-2025008506-A1 | 3-(2,3-DIFLUOROPHENOXY)AZETIDINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR USE IN THE TREATMENT AND/OR PREVENTION OF PATHOLOGICAL APATHY | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2025-01-09 | — | — | WO | disclosed |
| WO-2025008504-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3-(2,3-DIFLUOROPHENOXY)AZETIDINE AND USES THEREOF | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2025-01-09 | — | — | WO | disclosed |
| EP-3541784-B1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2023-09-13 | — | — | EP | disclosed |
| EP-3541784-B1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2023-09-13 | — | — | EP | disclosed |
| CN-109963834-B | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | 综合研究实验室瑞典股份公司 | 2023-04-14 | — | — | CN | disclosed |
| US-10875829-B1 | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2020-12-29 | — | — | US | disclosed |
| US-10875829-B1 | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2020-12-29 | — | — | US | disclosed |
| EP-3541784-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | Integrative Research Laboratories Sweden AB (SE) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018091687-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018091687-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875829-B1 | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | SLC18A1, CHRM1, CHRM2 | SLC6A2 21/4885SLC6A3 15/4885SLC6A4 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.